Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK4178116
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
**GSK4178116** is a vaccine candidate developed by GSK for the prevention of varicella (chickenpox) caused by the US strain of varicella-zoster virus (VZV). It is a live attenuated vaccine administered subcutaneously, targeting active immunization in individuals 12 months of age and older. The program aims to provide an improved seed strain for varicella vaccination.
- Other names
- investigational varicella vaccineinvestigational chickenpox vaccineVaricella New Strain
02
Targets
gE (VZV glycoprotein E)
Beyond the preview
Go deeper on GSK4178116.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK4178116.